Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent bolus vs continuous infusion of 3% sodium chloride in severe symptomatic hyponatremia
TCTR20240716002Phase 3Recruiting
- Sponsor
- Orakan Lanwong
- Start
- Jan 2024
- Countries
- 1
01
Overview
Phase 3 trial of sodium chloride in hyponatraemia (2 arms), sponsored by Orakan Lanwong. Primary endpoints: Efficacy of 3% sodium chloride administration strategy and Safety of 3% sodium chloride administration strategy. Started Jan 2024; status: recruiting.
02
Drugs
sodium chloride
03
Conditions
hyponatraemia
Beyond the preview
Go deeper on TCTR20240716002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240716002.